José Lopes, PhD, managing science editor —

A new study describes the rare case of a man who developed Lambert-Eaton myasthenic syndrome (LEMS) following treatment with the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for small-cell lung cancer (SCLC). The research, “Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with…

An animal model of Lambert-Eaton myasthenic syndrome (LEMS) has enabled better understanding of what drives the hallmark reduction in acetylcholine release as well as effective testing of treatment candidates. The study, “Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads,” appeared in…

A new case report describes a patient with Lambert-Eaton myasthenic syndrome (LEMS), small cell cervical cancer and breast cancer. This is the first report of a LEMS patient with two different cancers and underlines the importance of prompt diagnosis and treatment. The case study, “Lambert-Eaton…

A new case study describes a patient with Lambert-Eaton myasthenic syndrome (LEMS), myasthenia gravis (MG), and metastatic small cell lung cancer (SCLC). The report from Shandong, China, is titled “Coexistence of myasthenia gravis and Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient:…

Patients with Lambert-Eaton myasthenic syndrome (LEMS) and cerebellar ataxia may have autoantibodies against calcium channels, a Mayo Clinic study indicates. The study, titled “Calcium Channel Autoimmunity: Cerebellar Ataxia and Lambert-Eaton Syndrome Coexisting,” appeared in the journal Muscle & Nerve. Patients with LEMS typically show muscle…

Catalyst Pharmaceuticals filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for Firdapse (amifampridine) as a treatment for Lambert-Eaton myasthenic syndrome (LEMS). “We are pleased to reach this regulatory milestone and believe that our NDA submission contains all of the necessary information…